Alpelisib (ALP) plus endocrine therapy (ET) by last prior therapy in patients (pts) with PIK3CA-mutated hormone-receptor positive (HR plus ) human epidermal growth factor receptor-2-Negative (HER2-) advanced breast cancer (ABC): Additional study cohort in BYLieve

被引：0
|
作者：
Ciruelos, E. [1 ]
Lerebours, F. [2 ]
Ruiz Borrego, M. [3 ]
Bachelot, T. [4 ]
Polikoff, J. [5 ]
Chia, S. [6 ]
Juric, D. [7 ]
Turner, N. [8 ,9 ]
Ridolfi, A. [10 ]
Sophos, N. [11 ]
Cooper, B. [12 ]
Thuerigen, A. [13 ]
Rugo, H. S. [14 ]
机构：
[1] Univ Hosp 12 Octubre, Med Oncol, Madrid, Spain
[2] Hop Rene Huguenin, Dept Oncol, Inst Curie, St Cloud, France
[3] Hosp Univ Virgen del Rocio, Dept Oncol, Seville, Spain
[4] Ctr Leon Berard, Dept Oncol, Lyon, France
[5] Kaiser Permanente Southern Calif, Dept Oncol, San Diego, CA USA
[6] Univ British Columbia, Dept Med, Vancouver, BC, Canada
[7] Massachusetts Gen Hosp, Dept Oncol, Boston, MA 02114 USA
[8] Inst Canc Res, Dept Oncol, London, England
[9] Royal Marsden Hosp, London, England
[10] Novartis Pharmaceut, Rueil Malmaison, France
[11] Novartis Pharmaceut, Global Oncol, E Hanover, NJ USA
[12] Novartis Pharmaceut, Oncol Med Affairs, E Hanover, NJ USA
[13] Novartis Pharmaceut, Oncol Med Affairs, Basel, Switzerland
[14] UCSF Helen Diller Family Comprehens Canc Ctr, Breast Canc Ctr, San Francisco, CA USA
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
388TiP
引用
收藏
页码：141 / 141
页数：1
相关论文
共 50 条
  • [31] Effect of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy (≤6 mo or >6 mo) on alpelisib benefit in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) from BYLieve
    Chia, Stephen
    Ciruelos, Eva M.
    Rugo, Hope S.
    Lerebours, Florence
    Ruiz-Borrego, Manuel
    Drullinsky, Pamela
    Prat, Aleix
    Bachelot, Thomas
    Turner, Nicholas
    Gu, Ennan
    Arce, Christina
    Akdere, Murat
    Juric, Dejan
    CANCER RESEARCH, 2022, 82 (04)
  • [32] Patterns of disease management for European postmenopausal women with hormone-receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer
    Marinsek, N.
    Andre, F.
    Neven, P.
    Zhang, J.
    Degun, R.
    Benelli, G.
    Saletan, S.
    Jerusalem, G.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S411 - S411
  • [33] BYLieve: A phase 2 study of alpelisib with fulvestrant or letrozole for treatment of PIK3CA mutant, hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (aBC) progressing on/after cyclin-dependent kinase (CDK)4/6 inhibitor therapy
    Rugo, Hope S.
    Turner, Nicholas
    Chia, Stephen
    Ciruelos, Eva
    Nienstedt, Carolyn
    Ridolfi, Antonia
    Kong, Oliver
    Sankaran, Banu
    Juric, Dejan
    CANCER RESEARCH, 2018, 78 (04)
  • [34] Ribociclib plus endocrine therapy (ET) doublet combinations in hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Phase I clinical activity and impact of molecular alterations
    Julie, Dejan
    Campone, Mario
    Munster, Pamela
    Ismail-Khan, Roohi
    Estevez, Laura Garcia
    Chavez-MacGregor, Mariana
    Frassoldati, Antonio
    Hui, Rina
    Mayer, Ingrid A.
    Cortes, Javier
    Goncalves, Anthony
    De Boer, Richard H.
    Dirix, Luc
    Tolaney, Sara M.
    Lee, Soo Chin
    Maur, Michela
    Wang, Yingbo
    Su, Faye
    Dobson, Jason R.
    Germa, Caroline
    Hewes, Becker
    Bardia, Aditya
    CANCER RESEARCH, 2017, 77
  • [35] Ribociclib (RIB) plus endocrine therapy (ET) in Japanese women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC)
    Masuda, N.
    Noguchi, S.
    Ishikawa, T.
    Aruga, T.
    Kim, S. J.
    Toyama, T.
    Saeki, T.
    Saito, M.
    Yamanaka, T.
    Watanabe, J.
    Nakamura, S.
    Takahashi, M.
    Inoue, K.
    Gounaris, I.
    Han, Y.
    Samant, T. S.
    Gazdoiu, M.
    Ito, Y.
    ANNALS OF ONCOLOGY, 2018, 29
  • [36] Metformin (MET) for the prevention of Alpelisib (ALP)-related Hyperglycemia (HG) in PIK3CA-mutated, Hormone Receptor-Positive (HR[+]) HER2-Negative (HER2[-]) Advanced Breast Cancer (ABC): The METALLICA study
    Borrego, Manuel Ruiz
    Tolosa, Pablo
    Blanch, Salvador
    Fernandez, Adela
    Urriticoechea, Ander
    Blancas, Isabel
    Saura, Cristina
    Rojas, Beatriz
    Bermejo, Begona
    Ponce, Jose
    Gion, Maria
    Llabres, Elisenda
    Galve, Elena
    Cueva, Juan Fernando
    Lopez, Ana
    Alonso-Romero, Jose L.
    Gonzalez-Santiago, Santiago
    De Duenas, Eduardo Martinez
    Peralta, Fernando Gomez
    Ciruelos, Eva
    Perez-Garcia, Jose Manuel
    Llombart-Cussac, Antonio
    Cortes, Javier
    CANCER RESEARCH, 2023, 83 (05)
  • [37] EPIK-B2: A phase III study of alpelisib (ALP) as maintenance therapy with trastuzumab (T) and pertuzumab (P) in patients (pts) with PIK3CA-mutated (mut) human epidermal growth factor receptor-2-positive (HER2+) advanced breast cancer (ABC)
    Hurvitz, S. A.
    Chia, S. K. L.
    Ciruelos, E. M.
    Hu, X.
    Im, S-A.
    Janni, W.
    Jerusalem, G.
    Lacouture, M.
    O'Regan, R.
    Rugo, H. S.
    Yap, Y. S.
    Ghaznawi, F.
    Han, Y.
    Su, F.
    Chandarlapaty, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S389 - S390
  • [38] Population-adjusted comparison of SOLAR-1 and BOLERO-2: PFS with second-line alpelisib plus fulvestrant vs everolimus plus exemestane in postmenopausal pts with PIK3CA-mut hormone-receptor positive (HR plus ) human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer (ABC)
    Ciruelos, E. M.
    Delea, T.
    Moynahan, A.
    Mayer, I.
    Park, J.
    Chandiwana, D.
    Ridolfi, A.
    Lorenzo, I.
    Rugo, H. S.
    ANNALS OF ONCOLOGY, 2020, 31 : S74 - S74
  • [39] Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR plus )/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012
    Swallow, Elyse
    Zhang, Jie
    Thomason, Darren
    Tan, Ruo-Ding
    Kageleiry, Andrew
    Signorovitch, James
    CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (08) : 1537 - 1545
  • [40] Ribociclib plus letrozole in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Expanded safety analysis of the phase IIIb CompLEEment-1 trial
    Lu, Janice
    Cottu, Paul
    Martin, Miguel
    Zamagni, Claudio
    Prat, Aleix
    Chia, Stephen
    Jerusalem, Guy
    Rajappa, Senthil
    Timcheva, Constanta
    Zhukova, Lyudmila
    Zhou, Katie
    Wu, Jiwen
    Menon-Singh, Lakshmi
    De Laurentiis, Michelino
    CANCER RESEARCH, 2021, 81 (04)
12345